JP2021512929A5 - - Google Patents
Info
- Publication number
- JP2021512929A5 JP2021512929A5 JP2020542955A JP2020542955A JP2021512929A5 JP 2021512929 A5 JP2021512929 A5 JP 2021512929A5 JP 2020542955 A JP2020542955 A JP 2020542955A JP 2020542955 A JP2020542955 A JP 2020542955A JP 2021512929 A5 JP2021512929 A5 JP 2021512929A5
- Authority
- JP
- Japan
- Prior art keywords
- faah
- inhibitor
- pharmaceutical composition
- composition according
- targets
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1802326.7A GB201802326D0 (en) | 2018-02-13 | 2018-02-13 | Gene therapy |
| GB1802326.7 | 2018-02-13 | ||
| PCT/GB2019/050368 WO2019158909A1 (en) | 2018-02-13 | 2019-02-12 | Gene therapy of the faah pseudogene |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2021512929A JP2021512929A (ja) | 2021-05-20 |
| JP2021512929A5 true JP2021512929A5 (cg-RX-API-DMAC7.html) | 2022-02-21 |
Family
ID=61731413
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020542955A Pending JP2021512929A (ja) | 2018-02-13 | 2019-02-12 | Faah偽遺伝子の遺伝子療法 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US12241066B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3752608B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2021512929A (cg-RX-API-DMAC7.html) |
| CN (1) | CN112088214A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2019221798A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3090617A1 (cg-RX-API-DMAC7.html) |
| GB (1) | GB201802326D0 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2019158909A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2022018638A1 (en) | 2020-07-21 | 2022-01-27 | Crispr Therapeutics Ag | Genome-editing compositions and methods to modulate faah for treatment of neurological disorders |
| US20230313196A1 (en) * | 2020-07-23 | 2023-10-05 | John Mansell | Compositions and methods for treating pain and anxiety disorders |
| CN119932015B (zh) * | 2024-12-20 | 2025-11-25 | 中国科学院生物物理研究所 | 一种lncATRIG抑制剂及其在制备治疗胶质瘤的药物中的应用 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7541359B2 (en) | 2005-06-30 | 2009-06-02 | Janssen Pharmaceutica N.V. | N-heteroarylpiperazinyl ureas as modulators of fatty acid amide hydrolase |
| US20070088073A1 (en) | 2005-10-19 | 2007-04-19 | Allergan, Inc. | Method for treating pain |
| US9920317B2 (en) * | 2010-11-12 | 2018-03-20 | The General Hospital Corporation | Polycomb-associated non-coding RNAs |
| AU2012212088B2 (en) | 2011-02-04 | 2016-07-14 | The Scripps Research Institute | Alpha-ketoheterocycles and methods of making and using |
| JP6092870B2 (ja) | 2011-08-19 | 2017-03-08 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | メタ置換ビフェニル末梢に限局されたfaah阻害剤 |
-
2018
- 2018-02-13 GB GBGB1802326.7A patent/GB201802326D0/en not_active Ceased
-
2019
- 2019-02-12 EP EP19708599.6A patent/EP3752608B1/en active Active
- 2019-02-12 US US16/969,278 patent/US12241066B2/en active Active
- 2019-02-12 AU AU2019221798A patent/AU2019221798A1/en not_active Abandoned
- 2019-02-12 JP JP2020542955A patent/JP2021512929A/ja active Pending
- 2019-02-12 CA CA3090617A patent/CA3090617A1/en active Pending
- 2019-02-12 CN CN201980025731.2A patent/CN112088214A/zh active Pending
- 2019-02-12 WO PCT/GB2019/050368 patent/WO2019158909A1/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Gregoriou et al. | Management strategies of palmar hyperhidrosis: challenges and solutions | |
| Dong et al. | New biologics in psoriasis: an update on IL-23 and IL-17 inhibitors | |
| JP2023543218A5 (cg-RX-API-DMAC7.html) | ||
| Agarwal | High-dose AAV gene therapy deaths | |
| Uchida et al. | Epigenetic regulation of BDNF expression in the primary sensory neurons after peripheral nerve injury: implications in the development of neuropathic pain | |
| Shi et al. | MiR-145 ameliorates neuropathic pain via inhibiting inflammatory responses and mTOR signaling pathway by targeting Akt3 in a rat model | |
| WO2025127968A3 (ru) | Ингибитор ras-гтфазы и его применение для лечения онкологических заболеваний | |
| JP2017529382A5 (cg-RX-API-DMAC7.html) | ||
| Rojewska et al. | PD98059 influences immune factors and enhances opioid analgesia in model of neuropathy | |
| US20240108633A1 (en) | Method for preventing or treating disease or condition associated with antitumor agent | |
| JP2015520188A5 (cg-RX-API-DMAC7.html) | ||
| US20130210899A1 (en) | Method and Therapeutic for the Treatment and Regulation of Memory Formation | |
| EP3247340B1 (en) | Induced expression of brain derived neurotrophic factor (bdnf) for treatment of neuromuscular and/or neurodegenerative diseases | |
| CA2368814A1 (en) | Use of glucosylceramide synthesis inhibitors in therapy | |
| WO2004103297A3 (en) | Combination therapy with glatiramer acetate and mitoxantrone for the treatment of multiple sclerosis | |
| MX2022006858A (es) | Oligomeros antisentido para el tratamiento de condiciones y enfermedades. | |
| Sun et al. | The NLRP3-related inflammasome modulates pain behavior in a rat model of trigeminal neuropathic pain | |
| WO2018140934A1 (en) | Compositions and methods for hemoglobin production | |
| JP2022533981A5 (cg-RX-API-DMAC7.html) | ||
| MY200481A (en) | 1,3,4-oxadiazole derivative compounds as histone deacetylase 6 inhibitor, and the pharmaceutical composition comprising the same | |
| WO2023235509A3 (en) | Antisense oligomers for treatment of non-sense mediated rna decay based conditions and diseases | |
| Zhang et al. | Macrophage migration inhibitory factor (MIF) promotes intervertebral disc degeneration through the NF‐κB pathway, and the MIF inhibitor CPSI‐1306 alleviates intervertebral disc degeneration in a mouse model | |
| WO2022271699A3 (en) | Antisense oligomers for treatment of non-sense mediated rna decay based conditions and diseases | |
| US20210113654A1 (en) | Methods and Compositions to Alleviate Vascular Permeability | |
| JP4510451B2 (ja) | Stat−1依存的遺伝子の発現の調節 |